3rd Jan 2008 08:33
Skyepharma PLC03 January 2008 SkyePharma PLC U.S. FDA Approves New Sular Formulation LONDON, UK, and Atlanta, USA, 3 January 2008 -- SkyePharma PLC (LSE: SKP) andSciele Pharma, Inc (NASDAQ: SCRX) announce that the U.S. Food and DrugAdministration (FDA) has approved all four dosage strengths of the new Sular(R)formulation. Sular(R) is a calcium channel blocking agent for the treatment ofhigh blood pressure. The new Sular formulation utilizes SkyePharma's patentedGEOMATRIX(TM)technology, which provides a lower dose of Sular(R) for each of itscurrent doses. The expected launch for the new Sular(R) formulation is duringthe first quarter of 2008. SkyePharma will receive US$2 million (£1 million) upon the approval and also lowmid single digit royalties on net sales of new Sular(R). SkyePharma will also bemanufacturing the new Sular(R) formulation at our Lyon manufacturing facility. Dr Ken Cunningham, COO of SkyePharma said: "This new Sular(R) formulation is afurther example of the versatility of the GEOMATRIX(TM)technology and willprovide an additional revenue stream for SkyePharma." For further information please contact: SkyePharma PLC Frank Condella +44 20 7491 1777 Ken Cunningham Peter Grant Financial Dynamics (UK Enquiries) David Yates +44 20 7831 3113 Deborah Scott Trout Group (US Enquiries) Christine Labaree +1 617 583 1308 Seth Lewis About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops newformulations of known molecules to provide a clinical advantage and life-cycleextension. The Company has eleven approved products in the areas of oral,inhalation and topical delivery. The Group's products are marketed throughoutthe world by leading pharmaceutical companies. For more information, visit www.skyepharma.com About Sciele Pharma, Inc. Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketingand development of branded prescription products focused on Cardiovascular/Metabolic, Women's Health and Pediatrics. The Company's Cardiovascular/Metabolicproducts treat patients with high cholesterol, hypertension, high triglycerides,unstable angina and Type 2 diabetes; its Women's Health products are designed toimprove the health and well-being of women and mothers and their babies; and itsPediatrics products treat allergies, asthma, coughs and colds, and attentiondeficit/hyperactivity disorder (ADHD). Founded in 1992 and headquartered inAtlanta, Georgia, Sciele Pharma employs more than 900 people. The Company'ssuccess is based on placing the needs of patients first, improving health andquality of life, and implementing its business platform - an EntrepreneurialSpirit, Innovation, Speed of Execution, Simplicity, and Teamwork. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L